GoAI
Get started
Ribomic Inc. logo

Ribomic Inc.

4591.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥83.00

+¥2.00 · +2.47%

Aug 24, 11:12 AM JST

4591.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Yoshikazu Nakamura
Listed since
Sep 25, 2014
Employees
25

Market position

Day range

Current ¥83.00

52-week range

Current ¥83.00

Open
¥81.00
Previous close
¥81.00
Volume
467.1K
0.34× average
Average volume
1.39M
Average daily volume
Market cap
4.64B JPY
Beta
0.19
Market reference 1
50-day average
¥70.86
+17.13% above average
200-day average
¥79.81
+4.00% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.44B JPY
P/E (TTM)
-3.63×
P/B (TTM)
1.68×
P/S (TTM)
619.17×
EV / EBITDA
-2.03×
Earnings yield
-26.22%
Free cash flow yield
-25.66%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
51.37%
Operating margin
-16549.13%
Net margin
-15852.13%
Return on equity
-40.31%
Return on assets
-38.48%
Return on invested capital
-42.49%

Financial health

Debt / equity
0×
Current ratio
21.68×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends5048%-14919%-34886%-54854%Gross margin, FY2024: 56.43%Gross margin, FY2025: -33.17%Operating margin, FY2021: -2160.59%Operating margin, FY2022: -2707.39%Operating margin, FY2024: -49861.84%Operating margin, FY2025: -40237.73%Net margin, FY2021: -2082.28%Net margin, FY2022: -2505.73%Net margin, FY2024: -48359.71%Net margin, FY2025: -38178.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 56.43%. Gross margin FY2025 -33.17%. Operating margin FY2021 -2160.59%. Operating margin FY2022 -2707.39%. Operating margin FY2024 -49861.84%. Operating margin FY2025 -40237.73%. Net margin FY2021 -2082.28%. Net margin FY2022 -2505.73%. Net margin FY2024 -48359.71%. Net margin FY2025 -38178.67%.

Income trends

Revenue

3M JPY+42.38%

Operating income

−1.21B JPY-14.90%

Net income

−1.15B JPY-12.41%
Income trends across reported periods267.6M JPY−479.18M JPY−1.23B JPY−1.97B JPYRevenue, FY2021: 80.91M JPYRevenue, FY2022: 65.97M JPYRevenue, FY2024: 2.11M JPYRevenue, FY2025: 3M JPYOperating income, FY2021: −1.75B JPYOperating income, FY2022: −1.79B JPYOperating income, FY2023: −1.12B JPYOperating income, FY2024: −1.05B JPYOperating income, FY2025: −1.21B JPYNet income, FY2021: −1.68B JPYNet income, FY2022: −1.65B JPYNet income, FY2023: −1.02B JPYNet income, FY2024: −1.02B JPYNet income, FY2025: −1.15B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 80.91M JPY. Revenue FY2022 65.97M JPY. Revenue FY2024 2.11M JPY. Revenue FY2025 3M JPY. Operating income FY2021 −1.75B JPY. Operating income FY2022 −1.79B JPY. Operating income FY2023 −1.12B JPY. Operating income FY2024 −1.05B JPY. Operating income FY2025 −1.21B JPY. Net income FY2021 −1.68B JPY. Net income FY2022 −1.65B JPY. Net income FY2023 −1.02B JPY. Net income FY2024 −1.02B JPY. Net income FY2025 −1.15B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue3M JPY2.11M JPY—65.97M JPY80.91M JPY
Cost of goods sold4M JPY918K JPY10.5M JPY——
Gross profit−995K JPY1.19M JPY−10.5M JPY——
Research and development803.99M JPY666.99M JPY753.95M JPY1.49B JPY1.47B JPY
Selling, general, and administrative406.15M JPY384.79M JPY351.74M JPY360.71M JPY311.16M JPY
Operating expenses1.21B JPY1.05B JPY1.11B JPY1.85B JPY1.81B JPY
Interest income5.52M JPY1.74M JPY361K JPY1.39M JPY116K JPY
Depreciation and amortization4M JPY918K JPY10.5M JPY480K JPY15.51M JPY
Operating income−1.21B JPY−1.05B JPY−1.12B JPY−1.79B JPY−1.75B JPY
Net income−1.15B JPY−1.02B JPY−1.02B JPY−1.65B JPY−1.68B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-4.87

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-4.38-5.42-6.46-7.5Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 12, 2024: actual -5.56, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 12, 2025: actual -6.33, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 13, 2025: actual -6.33, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 12, 2025: actual -5.1, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual -6.09, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 12, 2026: actual -4.67, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual -7.21, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual -4.87, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates4.33M2.74M1.15M-435.56KQ3 '24Q4 '24Q1 '25Q2 '25Q1 '26Q2 '26Q3 '26
Q3 2024, reported Aug 9, 2024: actual 1M JPY, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 12, 2024: actual 1M JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 12, 2025: actual 107K JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 13, 2025: actual -107K JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 12, 2026: actual 750K JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual 3M JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual 4M JPY, estimate —, surprise —, Comparison unavailable.

4591.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥7,008

-0.04%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,799

+0.61%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,990

+0.38%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,205

+0.08%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,862

+1.01%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,392.5

+0.23%

Continue in GoAI

Research 4591.T

research.disclaimer